



Poor Immune Status and Systemic Disease Are Independently Associated with Mortality in AIDS-Related Kaposi Sarcoma in Nigeria

Citation

Agaba, Patricia, Halima Sule, Raphael Ojoh, Zakary Saidu, Mohamed Mua'zu, Oche Agbaji, John Idoko, Ernest Ekong, Robert Murphy, and Phyllis Kanki. 2012. Poor immune status and systemic disease are independently associated with mortality in aids-related kaposi sarcoma in nigeria. *Infectious Agents and Cancer* 7(Suppl 1): P7.

Published Version

doi:10.1186/1750-9378-7-S1-P7

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:10054140>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

POSTER PRESENTATION

Open Access

Poor immune status and systemic disease are independently associated with mortality in AIDS-related Kaposi Sarcoma in Nigeria

Patricia Agaba^{1*}, Halima Sule¹, Raphael Ojoh¹, Zakary Saidu¹, Mohamed Mua'zu¹, Oche Agbaji¹, John Idoko¹, Ernest Ekong², Robert Murphy³, Phyllis Kanki⁴

From 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Bethesda, MD, USA. 7-8 November 2011

Background

AIDS-related Kaposi's sarcoma (AIDS-KS) is the most common AIDS-associated malignancy and remains a significant cause of morbidity and mortality in sub-Saharan Africa. We describe the determinants of mortality among patients with AIDS-KS in a comprehensive HIV care and treatment program in Jos, Nigeria.

Material and methods

We collected epidemiologic, clinical, staging and survival data for 357 patients with a diagnosis of AIDS-KS enrolling for HIV-care at the Jos University Teaching Hospital. Patients were staged according to the AIDS Clinical Trials Group (ACTG) criteria, which are based on the evaluation of tumor extension (T), CD4+ cell count (I), and patient's systemic status (S), stratified by good (0) versus poor (1) risk. Information on survival was obtained through an active follow-up on verification of vital status of the patients. Survival analysis was computed by the Kaplan-Meier method, and the log-rank test was used to test the difference between subgroups.

Results

During the period of the study (2004-2008), there were 197 women (55.2%) and 160 (44.8%) men with AIDS-related Kaposi Sarcoma. Their mean age was 37±8 years and the median follow-up was 15 months (1-49 months). The median CD4+ and viral load were 107cells/mm³ and 58,561copies/ml respectively at baseline. Only 42 (11.8%)

were on HAART at KS diagnosis, however all patients were commenced on HAART in line with existing national guidelines subsequently. 262(74.4%) had poor immune system status (I1: CD4+<200cells/mm³), 77.5% had widespread tumor extension (T1) and 80.2% had systemic disease (S1). Poor immune system (I1) status (AOR 2.07, CI 1.25-3.42, p=0.002) and presence of systemic disease (S1) (AOR 2.10, CI 1.03-4.28, p=0.004) were independently associated with mortality.

Regarding ACTG classification, the 4-year survival rate was 67% for I0 vs 46% for I1 (p=0.05), 58% for S0 vs 49% for S1 (p=0.41), 60% for T0 vs 46% for T1 (p=0.19).

Conclusion

Poor immune status and systemic disease are independent predictors of mortality in patients with AIDS-KS in Nigeria.

Author details

¹APIN Centre, Jos University Teaching Hospital, Jos, Nigeria. ²AIDS Prevention Initiative Nigeria Plus, Abuja, Nigeria. ³Northwestern University Medical School, Chicago, IL, USA. ⁴Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.

Published: 19 April 2012

doi:10.1186/1750-9378-7-S1-P7

Cite this article as: Agaba et al: Poor immune status and systemic disease are independently associated with mortality in AIDS-related Kaposi Sarcoma in Nigeria. *Infectious Agents and Cancer* 2012 **7**(Suppl 1):P7.

* Correspondence: ellagaba@yahoo.com

¹APIN Centre, Jos University Teaching Hospital, Jos, Nigeria

Full list of author information is available at the end of the article